Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data

Inclusion criteria

• Discharged with chronic obstructive pulmonary disease;
• Hospitalized patients with COPD or AECOPD combined with lower respiratory tract infection;
• The treatment course of Xiyanping injection in the exposed group was ≥3 days, and the non-exposed group did not use Xiyanping injection;
• Study patients with complete medical records.

Exclusion criteria

• Researchers believe that multiple proprietary Chinese medicines with the same or similar functions (such as Tanreqing injection, Reduning injection, Yanhuning injection, etc.) have been used at the same time during treatment, resulting in no assessment of efficacy or safety;
• Patients with viral pneumonia or other systemic infection (such as urinary tract infection);
• Patients who do not use intravenous antibiotics;
• Refuse the case to be used by researchers.